Dr. Reddy's shares rise 3% on buying Haleon’s nicotine gum biz; here’s what brokerages say
The pharma major has agreed to acquire Haleon Plc’s Nicotinell and related portfolio outside of the U.S., for 500 million pounds.
The pharma major has agreed to acquire Haleon Plc’s Nicotinell and related portfolio outside of the U.S., for 500 million pounds.
The stellar run continues post-Covid as promoters reap benefits of growth in India and new launches in key markets.
The revenue witnessed 29% growth at ₹6,738.4 crore in the Q1 of FY24, against ₹5,215.4 crore YoY, driven by sales in North America, emerging markets and Europe.
The pharma major received “zero observations” post the USFDA pre-approval inspection (PAI) and a routine GMP inspection at the Andhra Pradesh facility
Dr. Reddy's posted a consolidated net profit of ₹1,187.6 crore in Q1FY23, registering a yearly growth of 108.05% and 1,257.25% on a quarterly basis.